Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Vaccines

Quick on Its Feet: Novavax Adapts to Continued Regulatory Uncertainty

After the delayed approval of its next-generation COVID-19 vaccine, Novavax now awaits the first meeting of the recently overhauled CDC vaccine advisory committee next week. Throughout a tumultuous season, the Maryland-based company is relying on agility and a diverse pipeline to stay ahead of rapidly changing regulations.

June 20, 2025

3 min read

Heather McKenzie

FDA

Gilead Wins Historic Approval for Twice-Yearly HIV Drug

Lenacapavir, to be marketed as Yeztugo, could “redefine the PReP market,” according to analysts.

June 18, 2025

2 min read

Dan Samorodnitsky

Contemporary art collage. employee mowing forward to success, stepping ladder of professional growth. Concept of business.

Obesity

Scholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody Combo

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped patients lose the same amount of weight as patients on tirzepatide alone while preserving more muscle mass.

June 18, 2025

2 min read

Dan Samorodnitsky

Business

More Than a One Trick Pony, Lilly Feeds Success Back Into Biotech

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the company is leveraging its unprecedented success in obesity to support young biotechs.

June 18, 2025

3 min read

Heather McKenzie

Creative photo poster picture collage collapsing dollar banknote arm holding cash money bankrupt decrease income funds loss.

Venture capitalists

More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds

EY’s 2025 Biotech Beyond Borders report provides a sobering snapshot of the industry’s financial health, with more and more companies facing cash runways of less than one year. The analyst firm’s leaders urge a return to basics for biotech.

June 18, 2025

4 min read

Ana Mulero

A man is holding an umbrella while standing on a cliff. The umbrella is green and the man is looking up at the sky. Concept of danger and uncertainty, as the man is on the edge of a cliff

Regulatory

FDA Chief’s New Voucher Program Could Ease Biotech Investors’ Anxiety

Industry watchers responded mostly positively to the commissioner’s new voucher program, but worries remain over staffing cuts at the agency.

June 18, 2025

2 min read

Annalee Armstrong

3d illustration of a black dragon flying on an extraterrestrial world with mountains beneath.

Neuropsychiatric disorders

Draig Takes Flight With $140M Series A To Advance Neuropsych Drugs

The U.K.-based biotech is set to enter mid-stage studies for its depression drug this year, while two other GABA_A modulators are poised for clinical trials in 2026.

June 18, 2025

2 min read

Tristan Manalac